Lexaria Bioscience Corp [NASDAQ: LEXX] stock went on an upward path that rose over 7.75% on Thursday, amounting to a one-week price increase of more than 25.41%.
Over the last 12 months, LEXX stock dropped by -27.14%. The one-year Lexaria Bioscience Corp stock forecast points to a potential upside of 74.5. The average equity rating for LEXX stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $29.92 million, with 19.46 million shares outstanding and 17.96 million shares in the current float. Compared to the average trading volume of 179.58K shares, LEXX stock reached a trading volume of 179733 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Lexaria Bioscience Corp [LEXX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LEXX shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LEXX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Price to Book ratio for the last quarter was 5.36, with the Price to Cash per share for the same quarter was set at 0.24.
LEXX Stock Performance Analysis:
Lexaria Bioscience Corp [LEXX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 25.41. With this latest performance, LEXX shares gained by 64.69% in over the last four-week period, additionally sinking by -14.86% over the last 6 months – not to mention a drop of -27.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LEXX stock in for the last two-week period is set at 71.15, with the RSI for the last a single of trading hit 0.1499, and the three-weeks RSI is set at 0.1189 for Lexaria Bioscience Corp [LEXX]. The present Moving Average for the last 50 days of trading for this stock 0.9879, while it was recorded at 1.3700 for the last single week of trading, and 1.3509 for the last 200 days.
Insight into Lexaria Bioscience Corp Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Lexaria Bioscience Corp [LEXX] shares currently have an operating margin of -1838.48% and a Gross Margin at 86.12%. Lexaria Bioscience Corp’s Net Margin is presently recorded at -1849.39%.
Lexaria Bioscience Corp (LEXX) Capital Structure & Debt Analysis
According to recent financial data for Lexaria Bioscience Corp. ( LEXX), the Return on Equity (ROE) stands at -145.34%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -135.93%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Lexaria Bioscience Corp’s Return on Invested Capital (ROIC) is -202.01%, showcasing its effectiveness in deploying capital for earnings.
Lexaria Bioscience Corp (LEXX) Efficiency & Liquidity Metrics
Based on Lexaria Bioscience Corp’s (LEXX) latest financial statements, the Debt-to-Equity Ratio is 0.02%, indicating its reliance on debt financing relative to shareholder equity.
Lexaria Bioscience Corp (LEXX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Lexaria Bioscience Corp. (LEXX) effectively leverages its workforce, generating an average of -$1627142.86 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.90% and a Quick Ratio of 3.90%, indicating strong ability to cover short-term liabilities.
LEXX Stock EPS
With the latest financial reports released by the company, Lexaria Bioscience Corp posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.04. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LEXX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lexaria Bioscience Corp go to 6.84%.
Lexaria Bioscience Corp [LEXX] Institutonal Ownership Details
There are presently around $11.75%, or 12.65%% of LEXX stock, in the hands of institutional investors. The top three institutional holders of LEXX stocks are: ARMISTICE CAPITAL, LLC with ownership of 1.02 million shares, which is approximately 7.3619%. INVENOMIC CAPITAL MANAGEMENT LP, holding 0.51 million shares of the stock with an approximate value of $$1.43 million in LEXX stocks shares; and INVENOMIC CAPITAL MANAGEMENT LP, currently with $$0.32 million in LEXX stock with ownership which is approximately 0.8284%.
